Targeted Drug Carriers: Biological Activity of the N-Acetylcysteine-Liposome System

  • Gary E. Isom
  • Dane O. Kildsig
Part of the Methodological Surveys in Biochemistry and Analysis book series (MSBA, volume 13)


Targeted drug carriers are designed to selectively deliver a pharmacological agent to the site of action in order to increase efficacy and minimize side-effects. Several different types of carriers ranging from antibodies to cellular systems are used to deliver drugs. Examples of the various types of carrier are discussed, with emphasis on the delivery of N-acetylcysteine (NAC) to the liver in the treatment of acetaminophen intoxication. In order to increase the efficacy of NAC as an antidote, a liposome drug-delivery system was developed which carries the compound directly to the liver. Positively charged NAC-liposomes, prepared by the chloroform film method, were highly effective in reversing acetaminophen-induced lethality in mice. This study provides excellent evidence that hepatic parenchymal cells take up liposomes rapidly, and it identifies the liver as a natural target organ for liposome drug delivery.


Drug Carrier Carrier System Liposome Drug Unilamellar Liposome Hepatocyte Plasma Membrane 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Gregoriadis, G. (1981) Lancet, 1 August, 241–247.Google Scholar
  2. 2.
    Rubens, R.D. (1974) Lancet, 23 March, 498–499.Google Scholar
  3. 3.
    O’Neill, G.J. (1979) in Drug Carriers in Biology and Medicine (Gregoriadis, G., ed.), Academic Press, New York, pp. 23–41.Google Scholar
  4. 4.
    Gregoriadis, G. (1982) Drugs 24, 261–266.CrossRefGoogle Scholar
  5. 5.
    Rogers, J.C. & Kornfield, S. (1971) Biochem. Biophys. Res. Comm. 45, 622–629.CrossRefGoogle Scholar
  6. 6.
    Dean, R.T. (1979) as for 3., pp. 71–86.Google Scholar
  7. 7.
    Trouet, A., Deprez-DeCampeneere, D., Baurain, R., Huybrechts, M. & Zenebergh, A. (1979) as for 3., pp. 87–105.Google Scholar
  8. 8.
    Ihler, G.M. (1979) as for 3., pp. 129–153.Google Scholar
  9. 9.
    Tyrrell, D.A., Heath, J.D., Colley, C.M. & Ryman, B.E. (1976) Biochim. Biophys. Acta 457, 259–302.CrossRefGoogle Scholar
  10. 10.
    Juliano, R.L. (1981) Trends Pharmacol. Sci. 3, 39–41.CrossRefGoogle Scholar
  11. 11.
    Gregoriadis, G. & Allison, A.C., eds. (1980) Liposomes in Biological Systems, Wiley, New York, pp. 25–86.Google Scholar
  12. 12.
    Jollow, D.J., Thorgeirsson, S.S., Potter, W.Z., Hashimoto, M. & Mitchell, J.R. (1974) Pharmacology 12, 251–275.CrossRefGoogle Scholar
  13. 13.
    Henson, J.A., Pohl, L.R., Monks, T.J. & Gillette, J.R. (198l) Life Sci. 29, 107–116.CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1984

Authors and Affiliations

  • Gary E. Isom
    • 1
  • Dane O. Kildsig
    • 1
  1. 1.Departments of Pharmacology-Toxicology and Industrial and Physical Pharmacy, School of Pharmacy and Pharmacal SciencesPurdue UniversityWest LafayetteUSA

Personalised recommendations